NewAmsterdam Pharma Company N.V. (NAMSW)
NGM
$16.56
-12.84%
Closing price as of 2026-07-28 · Source: TEK2day Finance
Key Metrics
Exchange
NGM
Currency
USD
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 19.1M | 348K | 32K | 3.0M |
| Operating Income | -35.6M | -55.1M | -66.0M | -58.4M |
| Net Income | -17.4M | -72.0M | -74.9M | -48.4M |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 102.7M | 14.1M | 45.6M | 22.5M |
| Operating Income | -3.6M | -183.0M | -176.3M | -225.7M |
| Net Income | -22.6M | -176.9M | -241.6M | -203.8M |